Anhedonia in Japanese patients with Parkinson's disease

Geriatrics and Gerontology International

Volumn 11, Issue 3, 2011, Pages 275-281

  Fujiwara, Shinya ^a   Kimura, Fumiharu ^a   Hosokawa, Takafumi ^a   Ishida, Shimon ^a   Sugino, Masakazu ^a   Hanafusa, Toshiaki ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

Dopaminergic reward pathway; Major depression disorder; Pramipexole; Self Rating Questionnaire for Depression; Snaith Hamilton Pleasure Scale

Indexed keywords

AMANTADINE; BROMOCRIPTINE; CABERGOLINE; LEVODOPA; PERGOLIDE; PRAMIPEXOLE; SELEGILINE; TRIHEXYPHENIDYL;

ADULT; AGED; ANHEDONIA; ARTICLE; CONTROLLED STUDY; DEPRESSION; DOPAMINERGIC NERVE CELL; DRUG EFFECT; FEMALE; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; SCORING SYSTEM; SOCIAL INTERACTION;

ADULT; AGED; DEPRESSIVE DISORDER; FEMALE; HUMANS; JAPAN; MALE; MIDDLE AGED; MOOD DISORDERS; PARKINSON DISEASE; PLEASURE; QUESTIONNAIRES; YOUNG ADULT;

EID: 79959549573     PISSN: 14441586     EISSN: 14470594     Source Type: Journal    
DOI: 10.1111/j.1447-0594.2010.00678.x     Document Type: Article

References (30)

1. Chaudhuri KR, Healy DG, Schapira AHV, National Institute for Clinical Excellence. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 2006; 5: 235-245.
2. Aarsland D, Larsen JP, Lim NG etal. Range of neuropsychiatric disturbances in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1999; 67: 492-496.
3. Yamamoto M. Depression in Parkinson's disease: its prevalence, diagnosis, and neurochemical background. J Neurol 2001; 248 (3): III/5-III/11.
4. Weintraub D, Morales KH, Moberg PJ etal. Antidepressant studies in Parkinson's disease: a review and meta-analysis. Mov Disord 2005; 20: 1161-1169.
5. Takeda M, Tanaka T. Depression in the elderly. Geriatr Gerontol Int 2010; 10: 277-279.
6. Snaith P. Anhedonia: a neglected symptom of psychopathology. Psychol Med 1993; 23: 957-966.
7. Cummings JL. Depression and Parkinson's disease: a review. Am J Psychiatry 1992; 149: 443-454.
8. Lemke MR. Dopamine agonists in the treatment of non-motor symptoms of Parkinson's disease: depression. Eur J Neurol 2008; Suppl 2: 9-14.
9. Mayberg HS, Solomon DH. Depression in Parkinson's disease: a biochemical and organic viewpoint. Adv Neurol 1995; 65: 49-60.
10. Nestler EJ, Carlezon WA Jr. The mesolimbic dopamine reward circuit in depression. Biol Psychiatry 2006; 59: 1151-1159.
11. Kvernmo T, Härtter S, Burger E. A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clin Ther 2006; 8: 1065-1078.
12. Wolters EC, Braak H. Parkinson's disease: premotor clinico-pathological correlations. J Neural Transm 2006; 70: 309-319.
13. Braak H, Del Tredici K, Rüb U etal. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24: 197-211.
14. Snaith RP, Hamilton M, Morley S, Humayan A, Hargreaves D, Trigwell P. A scale for the assessment of hedonic tone the Snaith-Hamilton Pleasure Scale. Br J Psychiatry 1995; 167: 99-103.
15. McKeith IG, Dickson DW, Lowe J, Emre M. Consortium on DLB. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005; 65: 1863-1872.
16. Berney A, Vingerhoets F, Perrin A etal. Effect on mood of subthalamic DBS for Parkinson's disease. A consecutive series of 24 patients. Neurology 2002; 59: 1427-1429.
17. Franken IHA, Rassin E, Muris P. The assessment of anhedonia in clinical and non-clinical populations: further validation of the Snaith-Hamilton Pleasure Scale (SHAPS). J Affect Disord 2007; 99: 83-89.
18. Abe T, Tsutsui H, Namba T. Studies on the self-rating questionnaire for the screening test of masked depression (SRQ-D). Jpn J Psychiatr Neurol 1972; 12: 243-247.
19. Rockliff BW. A brief self-rating questionnaire for depression (SRQ-D). Psychosomatics 1969; 10: 236-243.
20. Kuraoka M. Development and validation of self rating questionnaire-Depression II31 and SRQ-DII15: first report. Jpn J Psychosom Med 2007; 47: 855-863.
21. Hougaku H, Matsumoto M, Hata R etal. Therapeutic effect of lisuride maleate on post-stroke depression. Jpn J Geriat (Nippon Ronen Igakkai Zasshi) 1994; 31: 52-59.
22. Vingerhoets FJ, Villemure JG, Temperli P, Pollo C, Pralong E, Ghika J. Subthalamic DBS replaces levodopa in Parkinson's disease: two-year follow-up. Neurology 2002; 58: 396-401.
23. Pluck GC, Brown RG. Apathy in Parkinson's disease. J Neurol Neurosurg Psychiatry 2002; 73: 636-642.
24. Lemke MR, Brecht HM, Koester J, Kraus PH, Reichmann H. Anhedonia, depression, and motor functioning in Parkinson's disease during treatment with pramipexole. J Neuropsychiatry Clin Neurosci 2005; 17: 214-220.
25. Marsh L, McDonald WM, Cummings J, Ravina B, NINDS/NIMH Work Group on Depression and Parkinson's Disease. Provisional diagnostic criteria for depression in Parkinson's disease: report of an NINDS/NIMH Work Group. Mov Disord 2006; 21: 148-158.
26. Schrag A, Barone P, Brown RG etal. Depression rating scales in Parkinson's disease: critique and recommendations. Mov Disord 2007; 22: 1077-1092.
27. Rojo A, Aguilar M, Garolera MT, Cubo E, Navas I, Quintana S. Depression in Parkinson's disease: clinical correlates and outcome. Parkinsonism Relat Disord 2003; 10: 23-28.
28. Hasler G, Drevets WC, Manji HK, Charney DS. Discovering endophenotypes for major depression. Neuropsychopharmacology 2004; 29: 1765-1781.
29. Tippmann-Peikert M, Park JG, Boeve BF, Shepard JW, Silber MH. Pathologic gambling in patients with restless legs syndrome treated with dopaminergic agonists. Neurology 2007; 68: 301-303.
30. Maj J, Rogóz Z, Skuza G, Kołodziejczyk K. The behavioural effects of pramipexole, a novel dopamine receptor agonist. Eur J Pharmacol 1997; 324: 31-37.